Optical tomographic imaging of near infrared imaging agents quantifies disease severity and immunomodulation of experimental autoimmune encephalomyelitis in vivo

Journal of Neuroinflammation

Volumn 10, Issue , 2013, Pages

  Eaton, Valerie L ^a   Vasquez, Kristine O ^b   Goings, Gwendolyn E ^a   Hunter, Zoe N ^a   Peterson, Jeffrey D ^b   Miller, Stephen D ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b PERKINELMER INC   (United States)

Author keywords

Experimental autoimmune encephalomyelitis (EAE); Molecular imaging; Near infrared fluorescence; Protease

Indexed keywords

CATHEPSIN B; DIAGNOSTIC AGENT; NANOPARTICLE; NEAR INFRARED IMAGING AGENT; POLYGLACTIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DISEASE SEVERITY; EX VIVO STUDY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; FLUORESCENCE; FLUORESCENCE MOLECULAR TOMOGRAPHIC IMAGING; HISTOPATHOLOGY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IN VIVO STUDY; MOUSE; NONHUMAN; OPTICAL TOMOGRAPHY; SCORING SYSTEM; SPINAL CORD;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; MICE; RADIOPHARMACEUTICALS; SPINAL CORD; TOMOGRAPHY, OPTICAL;

EID: 84887520916     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-10-138     Document Type: Article

References (47)

1. Constantinescu CS, Farooqi N, O'Brien K, Gran B. Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol 2011, 164:1079-1106. 10.1111/j.1476-5381.2011.01302.x, 3229753, 21371012.
2. Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006, 129:1953-1971. 10.1093/brain/awl075, 16632554.
3. Steinman L. Multiple sclerosis: a two-stage disease. Nat Immunol 2001, 2:762-764. 10.1038/ni0901-762, 11526378.
4. Rangachari M, Kuchroo VK. Using EAE to better understand principles of immune function and autoimmune pathology. J Autoimmun 2013, http://dx.doi.org/10.1016/j.jaut.2013.1006.1008.
5. Kallen B, Nilsson O. Dissociation between histological and clinical signs of experimental auto-immune encephalomyelitis. Acta Pathol, Microbiol, et Immunol Scand - Sec A, Pathol 1986, 94:159-164.
6. Kuerten S, Addicks K, Lehmann PV. Studies on the CNS histopathology of EAE and its correlation with clinical and immunological parameters. Experimental Autoimmune Encephalomyelitis - Models, Disease Biology and Experimental Therapy 2012, 21-46. InTech, Weissert R.
7. Eckhardt J, Ostalecki C, Kuczera K, Schuler G, Pommer AJ, Lechmann M. Murine whole-organ immune cell populations revealed by multi-epitope-ligand cartography. J Histochem Cytochem 2013, 61:125-133. 10.1369/0022155412470140, 23160665.
8. Paul D, Cowan AE, Ge S, Pachter JS. Novel 3D analysis of Claudin-5 reveals significant endothelial heterogeneity among CNS microvessels. Microvasc Res 2013, 86:1-10.
9. Fu Y, Frederick TJ, Huff TB, Goings GE, Miller SD, Cheng JX. Paranodal myelin retraction in relapsing experimental autoimmune encephalomyelitis visualized by coherent anti-Stokes Raman scattering microscopy. J Biomed Opt 2011, 16:106006. 10.1117/1.3638180, 3206924, 22029353.
10. Radu CG, Shu CJ, Shelly SM, Phelps ME, Witte ON. Positron emission tomography with computed tomography imaging of neuroinflammation in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2007, 104:1937-1942. 10.1073/pnas.0610544104, 1783904, 17261805.
11. Abourbeh G, Theze B, Maroy R, Dubois A, Brulon V, Fontyn Y, Dolle F, Tavitian B, Boisgard R. Imaging microglial/macrophage activation in spinal cords of experimental autoimmune encephalomyelitis rats by positron emission tomography using the mitochondrial 18 kDa translocator protein radioligand [(1)(8)F]DPA-714. J Neurosci 2012, 32:5728-5736. 10.1523/JNEUROSCI.2900-11.2012, 22539835.
12. Barkhof F. MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS). Mult Scler 1999, 5:283-286.
13. Chen JW, Breckwoldt MO, Aikawa E, Chiang G, Weissleder R. Myeloperoxidase-targeted imaging of active inflammatory lesions in murine experimental autoimmune encephalomyelitis. Brain 2008, 131:1123-1133. 10.1093/brain/awn004, 18234693.
14. Serres S, Mardiguian S, Campbell SJ, McAteer MA, Akhtar A, Krapitchev A, Choudhury RP, Anthony DC, Sibson NR. VCAM-1-targeted magnetic resonance imaging reveals subclinical disease in a mouse model of multiple sclerosis. FASEB J 2011, 25:4415-4422. 10.1096/fj.11-183772, 3394669, 21908714.
15. Luo J, Ho P, Steinman L, Wyss-Coray T. Bioluminescence in vivo imaging of autoimmune encephalomyelitis predicts disease. J Neuroinflammation 2008, 5:6. 10.1186/1742-2094-5-6, 2267451, 18237444.
16. Wang C, Wu C, Popescu DC, Zhu J, Macklin WB, Miller RH, Wang Y. Longitudinal near-infrared imaging of myelination. J Neurosci 2011, 31:2382-2390. 10.1523/JNEUROSCI.2698-10.2011, 3044505, 21325505.
17. Ntziachristos V, Weissleder R. Experimental three-dimensional fluorescence reconstruction of diffuse media by use of a normalized Born approximation. Opt Lett 2001, 26:893-895. 10.1364/OL.26.000893, 18040483.
18. Schulz RB, Ripoll J, Ntziachristos V. Experimental fluorescence tomography of tissues with noncontact measurements. IEEE Trans Med Imaging 2004, 23:492-500. 10.1109/TMI.2004.825633, 15084074.
19. Mohajerani P, Adibi A, Kempner J, Yared W. Compensation of optical heterogeneity-induced artifacts in fluorescence molecular tomography: theory and in vivo validation. J Biomed Opt 2009, 14:034021. 10.1117/1.3149855, 19566314.
20. Getts DR, Martin AJ, McCarthy DP, Terry RL, Hunter ZN, Yap WT, Getts MT, Pleiss M, Luo X, King NJ, Shea LD, Miller SD. Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis. Nat Biotechnol 2012, 30:1217-1224. 10.1038/nbt.2434, 3589822, 23159881.
21. Turk B. Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov 2006, 5:785-799. 10.1038/nrd2092, 16955069.
22. Vasiljeva O, Reinheckel T, Peters C, Turk D, Turk V, Turk B. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr Pharm Des 2007, 13:387-403. 10.2174/138161207780162962, 17311556.
23. Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 2007, 59:251-287. 10.1124/pr.59.3.3, 2034302, 17878513.
24. Rosenberg GA. Matrix metalloproteinases in neuroinflammation. Glia 2002, 39:279-291. 10.1002/glia.10108, 12203394.
25. Bever CT, Garver DW. Increased cathepsin B activity in multiple sclerosis brain. J Neurol Sci 1995, 131:71-73. 10.1016/0022-510X(95)00039-5, 7561950.
26. Haves-Zburof D, Paperna T, Gour-Lavie A, Mandel I, Glass-Marmor L, Miller A. Cathepsins and their endogenous inhibitors cystatins: expression and modulation in multiple sclerosis. J Cell Mol Med 2011, 15:2421-2429. 10.1111/j.1582-4934.2010.01229.x, 21143385.
27. Stegbauer J, Lee DH, Seubert S, Ellrichmann G, Manzel A, Kvakan H, Muller DN, Gaupp S, Rump LC, Gold R, Linker RA. Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system. Proc Natl Acad Sci USA 2009, 106:14942-14947. 10.1073/pnas.0903602106, 2736426, 19706425.
28. Goodkin DE, Rooney WD, Sloan R, Bacchetti P, Gee L, Vermathen M, Waubant E, Abundo M, Majumdar S, Nelson S, Weiner MW. A serial study of new MS lesions and the white matter from which they arise. Neurology 1998, 51:1689-1697. 10.1212/WNL.51.6.1689, 9855524.
29. Bennett J, Basivireddy J, Kollar A, Biron KE, Reickmann P, Jefferies WA, McQuaid S. Blood-brain barrier disruption and enhanced vascular permeability in the multiple sclerosis model EAE. J Neuroimmunol 2010, 229:180-191. 10.1016/j.jneuroim.2010.08.011, 20832870.
30. Zhang Q, Bindokas V, Shen J, Fan H, Hoffman RM, Xing HR. Time-course imaging of therapeutic functional tumor vascular normalization by antiangiogenic agents. Mol Cancer Ther 2011, 10:1173-1184. 10.1158/1535-7163.MCT-11-0008, 21586628.
31. Stelter L, Evans MJ, Jungbluth AA, Longo VA, Zanzonico P, Ritter G, Bomalaski JS, Old L, Larson SM. Imaging of tumor vascularization using fluorescence molecular tomography to monitor arginine deiminase treatment in melanoma. Mol Imaging 2013, 12:67-73.
32. Mahmood U, Tung CH, Bogdanov A, Weissleder R. Near-infrared optical imaging of protease activity for tumor detection. Radiology 1999, 213:866-870. 10.1148/radiology.213.3.r99dc14866, 10580968.
33. Weissleder R, Tung CH, Mahmood U, Bogdanov A. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol 1999, 17:375-378. 10.1038/7933, 10207887.
34. Bremer C, Bredow S, Mahmood U, Weissleder R, Tung CH. Optical imaging of matrix metalloproteinase-2 activity in tumors: feasibility study in a mouse model. Radiology 2001, 221:523-529. 10.1148/radiol.2212010368, 11687699.
35. Kirsch DG, Dinulescu DM, Miller JB, Grimm J, Santiago PM, Young NP, Nielsen GP, Quade BJ, Chaber CJ, Schultz CP, Takeuchi O, Bronson RT, Crowley D, Korsmeyer SJ, Yoon SS, Hornicek FJ, Weissleder R, Jacks T. A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med 2007, 13:992-997. 10.1038/nm1602, 17676052.
36. Korideck H, Peterson JD. Noninvasive quantitative tomography of the therapeutic response to dexamethasone in ovalbumin-induced murine asthma. J Pharmacol Exp Ther 2009, 329:882-889. 10.1124/jpet.108.147579, 19293392.
37. Cortez-Retamozo V, Swirski FK, Waterman P, Yuan H, Figueiredo JL, Newton AP, Upadhyay R, Vinegoni C, Kohler R, Blois J, Smith A, Nahrendorf M, Josephson L, Weissleder R, Pittet MJ. Real-time assessment of inflammation and treatment response in a mouse model of allergic airway inflammation. J Clin Invest 2008, 118:4058-4066. 10.1172/JCI36335, 2579705, 19033674.
38. Deguchi JO, Aikawa M, Tung CH, Aikawa E, Kim DE, Ntziachristos V, Weissleder R, Libby P. Inflammation in atherosclerosis: visualizing matrix metalloproteinase action in macrophages in vivo. Circulation 2006, 114:55-62. 10.1161/CIRCULATIONAHA.106.619056, 16801460.
39. Nahrendorf M, Waterman P, Thurber G, Groves K, Rajopadhye M, Panizzi P, Marinelli B, Aikawa E, Pittet MJ, Swirski FK, Weissleder R. Hybrid in vivo FMT-CT imaging of protease activity in atherosclerosis with customized nanosensors. Arterioscler Thromb Vasc Biol 2009, 29:1444-1451. 10.1161/ATVBAHA.109.193086, 2746251, 19608968.
40. Izmailova ES, Paz N, Alencar H, Chun M, Schopf L, Hepperle M, Lane JH, Harriman G, Xu Y, Ocain T, Weissleder R, Mahmood U, Healy AM, Jaffee B. Use of molecular imaging to quantify response to IKK-2 inhibitor treatment in murine arthritis. Arthritis Rheum 2007, 56:117-128. 10.1002/art.22303, 17195214.
41. Peterson JD, Labranche TP, Vasquez KO, Kossodo S, Melton M, Rader R, Listello JT, Abrams MA, Misko TP. Optical tomographic imaging discriminates between disease-modifying anti-rheumatic drug (DMARD) and non-DMARD efficacy in collagen antibody-induced arthritis. Arthritis Res Ther 2010, 12:R105. 10.1186/ar3038, 2911895, 20509880.
42. Kennedy MK, Tan LJ, Miller SD, Dal Canto MC. Regulation of the effector stages of experimental autoimmune encephalomyelitis via neuroantigen-specific tolerance induction. J Immunol 1990, 145:117-126.
43. Tan LJ, Kennedy MK, Dal Canto MC, Miller SD. Successful treatment of paralytic relapses in adoptive experimental autoimmune encephalomyelitis via neuroantigen-specific tolerance. J Immunol 1991, 147:1797-1802.
44. Tan LJ, Kennedy MK, Miller SD. Regulation of the effector stages of experimental autoimmune encephalomyelitis via neuroantigen-specific tolerance induction. II. Fine specificity of effector T cell inhibition. J Immunol 1992, 148:2748-2755.
45. Getts DR, Turley DM, Smith CE, Harp CT, McCarthy D, Feeney EM, Getts MT, Martin AJ, Luo X, Terry RL, King NJ, Miller SD. Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L1+ and IL-10-producing splenic macrophages and maintained by T regulatory cells. J Immunol 2011, 187:2405-2417. 10.4049/jimmunol.1004175, 3159828, 21821796.
46. McRae BL, Vanderlugt CL, Dal Canto MC, Miller SD. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J Exp Med 1995, 182:75-85. 10.1084/jem.182.1.75, 2192093, 7540658.
47. Vanderlugt CL, Eagar TN, Neville KL, Nikcevich KM, Bluestone JA, Miller SD. Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis. J Immunol 2000, 164:670-678.